Recent News

• 04.09.2025 - Stifel 2025 Virtual Targeted Oncology Forum
• 04.04.2025 - Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
• 04.02.2025 - Syndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology Forum
• 04.02.2025 - Syndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology Forum
• 03.13.2025 - Barclays 27th Annual Global Healthcare Conference
• 03.05.2025 - Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
• 03.04.2025 - TD Cowen 45th Annual Health Care Conference
• 03.03.2025 - Syndax Fourth Quarter 2024 Conference Call
• 03.03.2025 - Syndax Fourth Quarter 2024 Conference Call
• 03.03.2025 - Syndax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Recent Filings

• 04.01.2025 - DEF 14A Other definitive proxy statements
• 04.01.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.01.2025 - ARS Annual Report to Security Holders
• 03.17.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.07.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 03.06.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.04.2025 - 144 Report of proposed sale of securities
• 03.04.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 03.03.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]